Cardiovascular Effects of the New Weight Loss Agents.
Cardiovascular Effects of the New Weight Loss Agents.
复制标题
新型减肥剂对心血管的影响。
DOI：
10.1016/j.jacc.2016.06.007
复制
发表时间：
2016
影响因子：
24
通讯作者：
Schwartzbard,ArthurZ
中科院分区：
文献类型：
--
作者：
Vorsanger,MatthewH;Subramanyam,Pritha;Weintraub,HowardS;Lamm,StevenH;Underberg,JamesA;Gianos,Eugenia;Goldberg,IraJ;Schwartzbard,ArthurZ
全球肥胖流行及其对心血管结局的影响是心脏病学界正在进行的辩论和研究的主题。众所周知，肥胖与多种心血管危险因素相关。虽然生活方式的改变是治疗的第一线，但它们往往不足以实现减肥目标。利拉鲁肽、纳洛酮/安非他酮和芬特明/托吡酯是最近被批准用于治疗肥胖的新药，但它们对心血管风险因素和结局的影响尚未得到很好的描述。本综述总结了目前这些新型药物在药物安全性、对主要心血管危险因素的影响、对心血管结局的影响、目前正在进行的结局研究以及不确定领域方面的数据。鉴于肥胖对心血管健康的影响，临床上迫切需要了解这些药物的作用，而不仅仅是减肥。
The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are often insufficient in achieving weight loss goals. Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well described. This review summarizes data currently available for these novel agents regarding drug safety, effects on major cardiovascular risk factors, impact on cardiovascular outcomes, outcomes research that is currently in progress, and areas of uncertainty. Given the impact of obesity on cardiovascular health, there is a pressing clinical need to understand the effects of these agents beyond weight loss alone.